Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07842640
PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

Sponsor: Ascletis Pharma (China) Co., Limited

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection

Official title: A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection, for Subcutaneous Use (Once-monthly Formulation) in Adult Participants With Obesity or Overweight

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2026-08-27

Completion Date

2027-06

Last Updated

2026-09-25

Healthy Volunteers

Yes

Interventions

DRUG

ASC35 Injection B, for subcutaneous use

ASC35 Injection B is an investigational once-monthly formulation of ASC35 administered by subcutaneous injection.

DRUG

ASC35 Placebo Injection B, for subcutaneous use

ASC35 Placebo Injection B is a placebo injection matching ASC35 Injection B

DRUG

Tirzepatide

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered by subcutaneous injection

Locations (1)

Ascletis Clinical Site

Baltimore, Maryland, United States